Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027

Unicycive Therapeutics (Nasdaq: UNCY) announced FDA acceptance of its resubmitted NDA for oxylanthanum carbonate, a treatment for hyperphosphatemia in chronic kidney disease patients. The FDA set a PDUFA date of March 25, 2027. The resubmission includes new manufacturing data. The company hopes for potential approval, pending FDA review and possible inspections.

Original reporting
Published Oct 21, 2026, 6:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 6:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027 — source image
Decision brief

The 30-second read

$UNCYBullishMed
01

Why it matters

The FDA acceptance clears a major regulatory step, setting a clear timeline for potential market entry.

02

Market read

Regulatory progress for a niche kidney‑disease drug could move the stock and influence peer biotech valuations.

03

What to watch

Potential competition from existing phosphate binders and the need for a pre‑approval inspection of the new vendor.

Relevance 8/10Novelty 8/10Timing: immediate

Background

Unicycive Therapeutics is a clinical‑stage biotech focused on kidney disease treatments.

Company-level read

Ticker impact

$UNCYBullishHigh confidence
Context

FDA accepted Unicycive's NDA resubmission for oxylanthanum carbonate and set a PDUFA date of March 25, 2027.

Expected impact

likely upside as investors price in a possible approval timeline

Evidence & confidence

Regulatory acceptance is a key catalyst for biotech valuations; the six‑month review window gives a clear timeline.

Market effects

May boost sentiment for kidney‑disease therapeutics and other phosphate‑binder developers.

Limited to US biotech sector; no broader regional effect.

Modest, confined to specialty pharma investors.

Counterpoint

Approval is not guaranteed; FDA could request further data, causing a price decline.

Key entities

  • Unicycive Therapeutics

    Biotech developing oxylanthanum carbonate for hyperphosphatemia.

  • FDA

    U.S. Food and Drug Administration overseeing the NDA review.

Related articles

$UNCYMed

Unicycive Therapeutics Reports Q3 2026 Results, $59 Million in Cash and Securities

Unicycive Therapeutics reported a Q3 2026 net loss of $7.0 million, or $0.25 per share, with $59 million in cash. The FDA accepted its OLC NDA resubmission, setting a March 25, 2027 PDUFA date. The company expects its cash runway to extend beyond 2027, including potential OLC launch costs. Research and development expenses decreased to $2.2 million from $3.0 million a year earlier, while general and administrative expenses increased to $6.6 million from $4.4 million.

$UNCYMed

Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update

Unicycive Therapeutics, Inc. (UNCY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update - New Drug Application (NDA) for oxylanthanum carbonate (OLC) accepted by the U.S. Food and Drug Administration (FDA), with an assigned Prescription Drug User Fee Act (

MedAI 8/10

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission and PDUFA

Unicycive Therapeutics announced the FDA accepted its resubmitted NDA for Oxylanthanum Carbonate (OLC), setting a PDUFA target action date of March 25, 2027. The resubmission addresses manufacturing deficiencies cited in a prior CRL. OLC is an investigational phosphate binder for CKD patients on dialysis, with potential market advantages due to its formulation.